The company
At S.A.F.AN. BIOINFORMATICS (Structural.And.Functional.Analysis) we specialize in chemoinformatic and structural bioinformatics research. We have built up our expertise working on applied research projects in partnership with some of the most important European pharmaceutical and biotech companies and developed our own technology to automate, sustain and enable more powerful drug-related chemoinformatic research. Today, S.A.F.AN. BIOINFORMATICS offers one of the most innovative and effective computational profiling technologies anywhere, supporting initial drug discovery and repositioning projects and greatly reducing costs for its customers.
Know-how, problem solving & consultancy
Innovative chemoinformatic solutions
Our Mission
Delivering compound -> protein binding predictions so reliable that no further experimental tests are needed.
More than 90% of drugs candidates fail during development, and this is the biggest contributor to the high costs of pharmaceutical R&D. Drug repositioning – finding new uses for existing drugs – can alleviate this problem. A significant advantage of drug repositioning over traditional drug development is that, since the drug has already passed its toxicity tests, its safety is known and the risks of failure are reduced. Drug repositioning is performed either with an experimental approach – ‘activity-based drug repositioning’, or by making use of a specific computational method. Compared with activity-based repositioning techniques, computational methods provide a faster repositioning process at a reduced cost.
We:
- Use our proprietary and very effective computational methods to explore small molecule and peptide binding to pharmaceutical targets.
- Screen molecules for new drugs or drugs repositioning ahead of more in-depth studies for a better success rate.
- Deliver results about your compounds/peptides with experimental-like accuracy at a lower cost and with computational turnaround time.
Out-of-Pocket Costs per molecule (M$)
Time (Years)
Paul et al. (2010) Nature Reviews Drug Discovery 9:203
S.A.F.AN. BIOINFORMATICS TECHNOLOGIES HELP YOU
FORECAST SUCCESSFUL AND UNSUCCESSFUL COMPOUNDS.
YOU CAN SAVE UP TO 200 M$ AND MORE THAN 10 YEARS OF WORK
Paul et al. (2010) Nature Reviews Drug Discovery 9:203
S.A.F.AN. BIOINFORMATICS TECHNOLOGIES HELP YOU
FORECAST SUCCESSFUL AND UNSUCCESSFUL COMPOUNDS.
YOU CAN SAVE UP TO 200 M$ AND
MORE THAN 10 YEARS OF WORK
If you are looking for drug repositioning opportunities, planning to in-license or out-licence small molecules S.A.F.AN. BIOINFORMATICS will help you evaluate more effectively your investments. Don’t hesitate to contact us here.
The executive Team
Luisa Pugliese
Founder & Ceo
Luisa Pugliese founded S.A.F.AN Bioinformatics in 2004. Luisa Pugliese specializes in large-scale computational chemical and biological analysis and is the leading force in the creation and evolution of S.A.F.AN.’s chemoinformatics platform.
Luisa holds a master’s degree in chemistry from the University of Turin and a PhD in Protein Crystallography from the University of Pavia. After post-doc appointments at the Université Libre de Bruxelles and CNRS Marseille, she was a group leader at the Istituto per la Ricerca e la Cura del Cancro at Candiolo, Italy before establishing S.A.F.AN. BIOINFORMATICS.
Marco Botta
Scientific Advisor
Hans Brauner Osborne
Scientific Advisor
Gianluca Catucci
Business Strategy Advisor
Wilma Lukas
Advisor
Collaborations
S.A.F.AN. BIOINFORMATICS participates in the bioPmed cluster dedicated to bio and medical technologies (health technologies).
We maintains close links with academic partners: Politecnico di Torino and the faculties of Medicine and of Computer Science of the Università di Torino.
We collaborate with Humana Biosciences, a pre-clinical contract research organization (CRO) with expertise in Respiratory, Gastrointestinal and Urogenital therapeutic areas. Its mission is to reduce the number of ineffective candidates moving through to the later stages of clinical investigation by developing innovative experimental models (in vitro and in vivo). Humana Biosciences also provides on-demand access to ethically obtained human tissues.
We collaborate with TissueGnostic, that has been a trendsetter for Tissue Cytometry and supplies the TissueFAXS Cytometry platform. The company has its headquarters in Vienna, Austria. Since its foundation in 2003 TissueGnostics has expanded into more than 30 countries on six continents and is proud of an ever-growing list of reference publications (1320 published journal articles as of August 2019).
We have been part of the H2020 CaSR Biomedicine European Training Network. Previously we participated in the Newprot FP7 project.
We are co-funded by the EOSC Future project under the European Union Horizon Programme call INFRAEOSC-03-2020 – Project ID 101017536 to perform an extensive validation of our core technology.
